| Cancer treatment-like immunotherapy thoughts |
|
|
1
|
| 1
|
|
01/23/2016 23:07
dpjcrfsh 
|
01/23/2016 23:07
dpjcrfsh
|
Cancer treatment-like immunotherapy thoughts
With all the amazing progress that's been going on in cancer treatments using special immunotherapy to train the body's immune system to attack cancer cells, I can't help but wonder if this sort of treatment could be in the horizon for Dupuytren's in the not too distant future (ten years?). Have there been any discussions on this possibility?
|
|
|
|
|
01/31/2016 04:18
Bedwards 
|
01/31/2016 04:18
Bedwards
|
Re: Cancer treatment-like immunotherapy thoughts
Isn't that what radiation therapy does? That's how it was explaned to me.
|
|
|
|
|
10/05/2018 19:52
PaulG
|
10/05/2018 19:52
PaulG
|
Re: Cancer treatment-like immunotherapy thoughts
Good question but very little discussion on this so far.
To my knowledge the apoptotic drugs used for certain sarcomas target a marker that is not present in Duputren's.
Natitoclax (and others) target BCL proteins to allow for apoptosis in tumors, however BCL is not found in Dups tissues. There are studies that show that such drugs increase effectiveness of tumor reduction following radiation.
The mechanisms for inhibition of scar tissue apoptosis is still not well understood in Dupuytren's. It would be nice if some gains were made in this area for sure.
Edited 10/15/18 23:03
|
|
|
|
|
11/13/2018 05:04
stephenp
|
11/13/2018 05:04
stephenp
|
Re: Cancer treatment-like immunotherapy thoughts
Targeted immunotherapy is based on the finding that some tumours have unique markers or antigens. The immune system can be trained through the use of various antigen delivery systems to start an immune response against those tumour specific antigens. The immune response them attacks the tumour.
As far as I am aware the cells (fibroblasts) laying down the collagen do not have unique specific markers but that would seem to warrant more research. I was aware of a few researchers looking a cells from DD patients taken during surgery. I do not know where this research has gone if anywhere.
Since there are no unique markers or antigens, there is nothing specific that is not on normal cells to act as a target.
RT acts on cells that are highly metabolically active which is why RT is effective in the treatment of some cancers and in treating DD where the feral fibroblasts seem to be more active and susceptible to radiation.
|
|
|
|
|
|
1
|
| 1
|
612 users online
Login
